NASDAQ$DXCM
DexCom Inc · Q3 2025 earnings
Q3 2025 earnings · · After market close · Investor relations
Briefing
DexCom reported Q3 2025 revenue of $1.21B with net income of $283.8M and diluted EPS of $0.70.
Third-quarter revenue was $1.21 billion on CGM adoption. Net income was $283.8 million and diluted EPS was $0.70. International expansion and type 2 indications support volume growth.
- Q3 revenue $1.21B; CGM installed base growing.
- Diluted EPS $0.70; net income $283.8M.
- Pharmacy channel and Medicare coverage expand access.
- Competitive CGM pricing and manufacturing scale remain focal.
Headline financials
Revenue & EPS history
DexCom · Revenue · Quarterly
$1.21B
Forward guidance
The quarterly filing discusses operating priorities, capital returns, and sector risks.
Tailwinds
- MD&A highlights liquidity and core business trends.
- Management commentary on segment performance.
Headwinds
- Macro, rates, or input costs may pressure margins.
- One-time items can affect YoY comparability.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2025
+1.6%
Avg return
Earnings day
+2.0%
Avg return
5 days after
+1.8%
Avg return
30 days after
56%
36 / 64 earnings
Positive
+31.1%
Q2 2018
Best reaction
-42.8%
Q2 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +9.8% | +1.4% | +23.8% | |
| Q4 2025 | +7.6% | +11.9% | -1.3% | |
| Q3 2025 | +1.6% | -13.1% | -6.9% | |
| Q1 2025 | +16.0% | +18.6% | +22.1% | |
| Q4 2024 | +5.9% | +6.6% | -15.9% | |
| Q3 2024 | +1.3% | -0.3% | +0.5% | |
| Q2 2024 | -42.8% | -37.7% | -33.8% | |
| Q1 2024 | -9.8% | -7.6% | -7.6% | |
| Q4 2023 | -4.8% | -7.6% | +6.8% | |
| Q3 2023 | +5.9% | +5.3% | +33.9% | |
| Q2 2023 | +1.3% | -6.6% | -22.9% | |
| Q1 2023 | -2.9% | -5.5% | -7.9% | |
| Q4 2022 | +7.3% | +7.9% | -1.9% | |
| Q3 2022 | +17.8% | +16.0% | +9.2% | |
| Q2 2022 | -4.3% | +2.9% | -1.5% | |
| Q1 2022 | -1.1% | -4.3% | -30.0% | |
| Q4 2021 | -6.1% | -6.8% | -12.9% | |
| Q3 2021 | +11.6% | +14.5% | +6.0% | |
| Q2 2021 | +12.1% | +13.3% | +13.2% | |
| Q1 2021 | -9.3% | -12.8% | -13.2% | |
| Q4 2020 | +3.3% | +1.2% | -10.4% | |
| Q3 2020 | -16.5% | -23.5% | -25.2% | |
| Q2 2020 | +0.9% | +2.9% | +1.0% | |
| Q1 2020 | +3.1% | +1.9% | +8.0% | |
| Q4 2019 | +15.4% | +20.3% | -0.8% | |
| Q3 2019 | +26.8% | +33.9% | +46.4% | |
| Q2 2019 | -5.2% | -9.1% | +9.7% | |
| Q1 2019 | -0.6% | +0.9% | +0.2% | |
| Q4 2018 | -5.9% | -4.1% | -11.3% | |
| Q3 2018 | +10.5% | +14.2% | -1.0% | |
| Q2 2018 | +31.1% | +28.1% | +51.8% | |
| Q1 2018 | +14.2% | +16.6% | +25.6% | |
| Q4 2017 | -1.4% | +6.6% | +3.0% | |
| Q3 2017 | +6.1% | +11.1% | +29.0% | |
| Q2 2017 | +7.1% | +6.8% | +12.0% | |
| Q1 2017 | -7.1% | -4.3% | -16.0% | |
| Q4 2016 | +2.9% | +1.6% | +7.3% | |
| Q3 2016 | -19.6% | -20.9% | -19.0% | |
| Q2 2016 | -1.9% | -1.5% | -1.0% | |
| Q1 2016 | -5.5% | — | — | |
| Q4 2015 | +1.4% | — | — | |
| Q3 2015 | -3.0% | — | — | |
| Q2 2015 | +9.9% | — | — | |
| Q1 2015 | -0.7% | — | — | |
| Q4 2014 | +0.6% | — | — | |
| Q3 2014 | +15.7% | — | — | |
| Q2 2014 | +10.9% | — | — | |
| Q1 2014 | -1.8% | — | — | |
| Q4 2013 | -3.1% | — | — | |
| Q3 2013 | +16.4% | — | — | |
| Q2 2013 | +18.7% | — | — | |
| Q1 2013 | +10.0% | — | — | |
| Q4 2012 | +9.2% | — | — | |
| Q3 2012 | -1.5% | — | — | |
| Q2 2012 | +2.4% | — | — | |
| Q1 2012 | +2.0% | — | — | |
| Q4 2011 | -3.6% | — | — | |
| Q3 2011 | -16.2% | — | — | |
| Q2 2011 | -17.7% | — | — | |
| Q1 2011 | -1.7% | — | — | |
| Q4 2010 | +5.3% | — | — | |
| Q3 2010 | -22.1% | — | — | |
| Q2 2010 | +5.5% | — | — | |
| Q1 2010 | -9.2% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro